ABOUT DIANT PHARMA
DIANT® Pharma, Inc., established in 2019, has introduced cutting-edge, end-to-end manufacturing platforms distinguished by its adaptability and seamlessly integrating nanoparticle generation with all downstream operations as a closed system. This innovative framework delivers a multitude of advantages, including a more compact production footprint, decreased facility requirements, heightened scalability, reduced human intervention, elimination of holding intervals, and precise regulation over particle size distribution.
DIANT’s innovative blueprint for continuous nanoparticle production is predicated on an end-to-end manufacturing platform tailored for nucleic acid–LNPs, placing an emphasis on a closed-loop system design and exhaustive process monitoring protocols. The proprietary DIANT® Jet technology serves as the linchpin for efficient LNP generation through controlled mixing methodologies, ensuring the production of LNPs featuring unwavering uniformity, scalability across diverse applications, and exceptional particle characteristics.
SOLUTIONS
-
![DIANT - LARU Discovery]( "Jet-Based Nanoparticle Formulation At Research Scale")
Jet-Based Nanoparticle Formulation At Research ScaleDeveloping nanoparticle formulations requires a scalable solution that replicates manufacturing conditions at a small scale. Turbulent jet mixing enables linear scalability while conserving materials.
-
![DIANT - nanoparticle]( "Delivering Best-In-Class Nanoparticles")
Delivering Best-In-Class NanoparticlesAchieve uniformity and control in nanoparticle synthesis with an advanced system that streamlines production, reduces human intervention, and delivers exceptional particle characteristics for diverse applications.
VIDEOS
Transforming Nanoparticles By Continuous Manufacturing
Discover how continuous manufacturing of nanoparticles can improve process efficiency, reduce costs, and increase the quality of the final drug product.
Groundbreaking Nanoparticle Processing Technology
Unlock next-generation nanoparticle and LNP manufacturing. Achieve high throughput, minimal waste, and superior quality with a compact, automated, and contamination-controlled system.
CONTACT INFORMATION
DIANT Pharma
130 Utopia Rd
Manchester, CT 06042
UNITED STATES
Phone: 860-202-8752
Contact: Jim Ziogas, Sales Engineer
FEATURED INSIGHTS
Comparing Microfluidic Mixing With A Turbulent Jet Approach For Lipid Nanoparticles
A comparative study examines how two mixing technologies, microfluidic and turbulent jet, influence the attributes of lipid nanoparticles and their suitability for different stages of drug development.
-
![GettyImages-1351826681 vaccines]( "Performance Of The DIANT sp2TFF System Across Different Flow Regimes")
Performance Of The DIANT sp2TFF System Across Different Flow RegimesA dual-stage TFF system has been proven to reliably perform buffer exchange and concentration under both high- and low-flow conditions, demonstrating its versatility and low-pressure stability.
-
![GettyImages-2174865889 lab, research]( "Tangential Flow Filtration Of LNPs Results In 10X Concentration Within 20 Minutes")
Tangential Flow Filtration Of LNPs Results In 10X Concentration Within 20 MinutesDive into a study that details how a single-pass tangential flow filtration system can achieve a tenfold concentration of liposomal nanoparticles in under 20 minutes.
-
![GettyImages-1409578453 LNP]( "Mixing Technology: Linear Scalability And Mixing Precision For Nanoparticle Formulation")
Mixing Technology: Linear Scalability And Mixing Precision For Nanoparticle FormulationFind out how you can achieve precise control and linear scalability in nanoparticle formulation with mixing technology that minimizes batch-to-batch variability and simplifies the scale-up process.
-
![GettyImages-1298788278 drug manufacturing]( "Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing")
Improving U.S. Drug Supply Stability Through Continuous Nanoparticle ProcessingLearn about a continuous manufacturing platform designed to help overcome challenges in domestic pharmaceutical production, including scale-up barriers and production variability.
-
![GettyImages-2172807364 vaccine, digital]( "Bridging Advanced Manufacturing, Pharma 4.0, And RNA Therapeutics")
Bridging Advanced Manufacturing, Pharma 4.0, And RNA TherapeuticsPharma 4.0 and RNA therapeutics are transforming drug manufacturing. Discover how digital tools, real-time monitoring, and scalable platforms are enhancing quality and efficiency in this evolving landscape.
-
![iStock-1140779660-drug-development-lab]( "Enabling Continuous Manufacturing For CAR-T And LNP-Based Therapies")
Enabling Continuous Manufacturing For CAR-T And LNP-Based TherapiesBreakthrough therapies are challenged by complex, batch-based manufacturing. A novel, integrated system enables continuous processing, improving consistency and reducing manual handling for advanced modalities.
-
![GettyImages-2032712798-lab-vaccine-microscope-research-development]( "Transforming Nanoparticle Processing Through Innovation")
Transforming Nanoparticle Processing Through InnovationLearn about an innovative closed, single-use system and proprietary mixing technology aimed at improving reproducibility and reducing contamination risks in biopharma manufacturing.
-
![GettyImages-1418152314]( "Unpacking The Importance Of Lipid Nanoparticle Production Platforms")
Unpacking The Importance Of Lipid Nanoparticle Production PlatformsBatch processing platforms for LNPs lack efficiency, appropriate controls, and yield optimization. Continuous manufacturing platforms may address some of those issues.
